Results 211 to 220 of about 8,248,666 (375)

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

A novel Compound-Pareto model with applications and reliability peaks above a random threshold value at risk analysis. [PDF]

Sci Rep
Abiad M, El-Raouf MMA, Yousof HM, Bakr ME, Samson Balogun O, Yusuf M, Mekiso GT, Tashkandy YA.   +7 more
europepmc   +1 more source

Incremental value of risk factor variability for cardiovascular risk prediction in individuals with type 2 diabetes: results from UK primary care electronic health records. [PDF]

Int J Epidemiol, 2022
Xu Z, Arnold M, Sun L, Stevens D, Chung R, Ip S, Barrett J, Kaptoge S, Pennells L, Di Angelantonio E, Wood AM.   +10 more
europepmc   +1 more source

Integration des Marktliquiditätsrisikos in das Risikoanalysekonzept des Value at Risk

, 2012
Florian Völker, Heinz Cremers, Christof Panzer   +2 more
openalex   +1 more source

Value of Cardiovascular Magnetic Resonance Imaging–Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy

, 2017
Ramdas G. Pai, Padmini Varadarajan, Jean L. Rouleau, Amanda Stebbins, Eric J. Velazquez, Hussein R. Al‐Khalidi, Gerald M. Pohost   +6 more
openalex   +2 more sources

Worst-Case Value at Risk of Nonlinear Portfolios

Management Sciences, 2013
Steve Zymler, D. Kuhn, B. Rustem
semanticscholar   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Changes in Phenylacetylglutamine Levels Provide Add-On Value in Risk Stratification of Hypertensive Patients: A Longitudinal Cohort Study. [PDF]

Metabolites
Xu X, Jia L, Qiao B, Gong Y, Gao S, Wang Y, Du J.   +6 more
europepmc   +1 more source

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis. [PDF]

BMJ Open Gastroenterol, 2021
Sripongpun P, Pongpaibul A, Charatcharoenwitthaya P.   +2 more
europepmc   +1 more source

A Study on the Effect of Fair Value Hierarchy upon Cost of Capital Through the Convergence of Market Risk Management and Audit Quality

, 2015
Hyun-Taek Oh
openalex   +2 more sources